Table 3.
Survival of MM patients with high-risk FISH compared with those without high-risk FISH
| FISH | Np/Na | End point | Therapy | Present | Absent | Comment | Ref |
|---|---|---|---|---|---|---|---|
| Conventional therapy | |||||||
| t(4;14) | 42/290 | 3-y OS | VBMCP | 24% | 64% | E9486 | 13 |
| 100/616 | 3-y OS | VAD + ASCT × 2 | 55% | 80% | IFM-99 | 25 | |
| 98/414 | 3-y OS | VAD + ASCT × 1/2 | 40% | 72% | IFM-2005 | 68 | |
| del17p | 37/308 | 3-y OS | VBMCP | 32% | 68% | E9486 | 13 |
| 58/474 | 3-y OS | VAD + ASCT × 2 | 50% | 78% | IFM-99 | 25 | |
| 119/393 | 3-y OS | VAD + ASCT × 1 | 49% | 82% | IFM-2005 | 68 | |
| Unfavorable FISH | 141/166 | 3-y OS | CVAD + ASCT × 1 | 58% | 81% | MRC IX intensive | 62 |
| 90/125 | 3-y OS | MP | 26% | 48% | MRC IX non-intensive | 61 | |
| 98/129 | 3-y OS | Placebo maintenance | 69% | 72% | MRC IX maintenance | 39 | |
| 18/111 | 3-y OS | VBMCP/VBAD +Bz × 2 + ASCT × 1 | 48% | 84% | GEM2005 <65 | 63 | |
| Thalidomide | |||||||
| t(4;14) | 57/181 | 3-y PFS | TD + ASCT × 2 + TD | 20% | 48% | GIMEMA | 102 |
| 26/156 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 44% | 79% | HOVON65/GMMG-HD4 | 29 | |
| del17p | 21/161 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 17% | 79% | HOVON65/GMMG-HD4 | 29 |
| Unfavorable FISH | 43/302 | 5-y OS | Thal induction, consolidation, maintenance | 56% | 72% | Total Therapy 2 | 18 |
| 152/167 | 3-y OS | CTD + ASCT × 1 | 59% | 82% | MRC IX intensive | 62 | |
| 96/129 | 3-y OS | CTDa | 58% | 78% | MRX IX non-intensive | 61 | |
| 99/126 | 3-y OS | Thalidomide maintenance | 45% | 76% | MRX IX maintenance | 39 | |
| 17/110 | 3-y OS | TD + ASCT × 1 | 56% | 86% | GEM2005 < 65 | 63 | |
| Lenalidomide | |||||||
| t(4;14) | 28/102 | Median OS | RD in RRMM | 18 m | 23 m | MM-016 | 103 |
| 26/158 | Median OS | RD in RRMM | 9 m | 15 m | IFM | 83 | |
| 152/355 | Median PFS | Lenalidomide maintenance | 27 m | 42 m | IFM-2005 | 68 | |
| del17p | 12/118 | Median OS | RD in RRMM | 4 m | 23 m | MM-016 | 103 |
| 6.6% | Median PFS | Lenalidomide maintenance | 29 m | 42 m | IFM-2005 | 68 | |
| Unfavorable FISH | 16/84 | 3-y OS | RD | 77% | 86% | Mayo Clinic | 76 |
| 21/105 | 2-y OS | RD | 76% | 91% | E4A03 | 104 | |
| Bortezomib | |||||||
| t(4;14) | 106/401 | 4-y OS | VD + ASCT × 1 | 63% | 85% | IFM-2005 | 68 |
| 53/183 | 3-y PFS | VTD + ASCT × 2 + BzTD | 65% | 61% | GIMEMA | 102 | |
| 24/148 | 3-y OS | VAD + ASCT × 1 + Bz | 66% | 82% | HOVON65/GMMG-HD4 | 29 | |
| del17p | 54/453 | 4-y OS | VD + ASCT × 1 | 50% | 79% | IFM-2005 | 68 |
| 16/158 | 3-y OS | VAD + ASCT × 1 + Bz | 69% | 82% | HOVON65/GMMG-HD4 | 29 | |
| Unfavorable FISH | 18/112 | 3-y OS | VTD + ASCT × 1 | 60% | 88% | GEM2005 <65 | 63 |
| 44/188 | 3-y OS | VMP/BzTP, BzT/BzP | 55% | 73% | GEM2005 <65 | 73 | |
| 28/140 | 3-y OS | VMP | 56% | 71% | VISTA | 72 | |
Adapted from Bergsagel et al.58